Which has preferable valuation & earnings, CVRX or NPCE?

NeuroPace has higher revenue and earnings than CVRx. NeuroPace is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CVRx $56.65M 2.33 -$53.31M -$2.02 N/A NeuroPace $99.99M 5.27 -$21.47M -$0.65 N/A

Is CVRX or NPCE more profitable?

NeuroPace has a net margin of -21.67% compared to CVRx's net margin of -89.14%. NeuroPace's return on equity of -108.20% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets CVRx -89.14% -120.76% -48.38% NeuroPace -21.67% -108.20% -18.50%

Which has stronger earnings and valuation, CVRX or KIDS?

OrthoPediatrics has higher revenue and earnings than CVRx. OrthoPediatrics is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CVRx $56.65M 2.33 -$53.31M -$2.02 N/A OrthoPediatrics $243.30M 2.06 -$39.65M -$1.68 N/A

Is CVRX or KIDS more profitable?

OrthoPediatrics has a net margin of -16.31% compared to CVRx's net margin of -89.14%. OrthoPediatrics' return on equity of -7.01% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets CVRx -89.14% -120.76% -48.38% OrthoPediatrics -16.31% -7.01% -4.86%

Does the media prefer CVRX or KIDS?

In the previous week, OrthoPediatrics had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for OrthoPediatrics and 2 mentions for CVRx. OrthoPediatrics' average media sentiment score of 0.59 beat CVRx's score of 0.00 indicating that OrthoPediatrics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CVRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OrthoPediatrics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLPT or CVRX more profitable?

ClearPoint Neuro has a net margin of -71.57% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ClearPoint Neuro -71.57% -140.96% -36.98% CVRx -89.14% -120.76% -48.38%

Which has better earnings and valuation, CVRX or DCTH?

Delcath Systems has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CVRx $56.65M 2.33 -$53.31M -$2.02 N/A Delcath Systems $85.23M 5.19 $2.70M $0.01 1,281.00

Is CVRX or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to CVRx's net margin of -89.14%. Delcath Systems' return on equity of 0.51% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets CVRx -89.14% -120.76% -48.38% Delcath Systems 0.62% 0.51% 0.46%

Does the media prefer CVRX or DCTH?

In the previous week, CVRx had 1 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for CVRx and 1 mentions for Delcath Systems. CVRx's average media sentiment score of 0.00 equaled Delcath Systems'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CVRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CVRX or SI more profitable?

Shoulder Innovations has a net margin of -81.78% compared to CVRx's net margin of -89.14%. Shoulder Innovations' return on equity of -35.11% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets CVRx -89.14% -120.76% -48.38% Shoulder Innovations -81.78% -35.11% -20.58%

Does the media favor CVRX or SI?

In the previous week, Shoulder Innovations had 1 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Shoulder Innovations and 2 mentions for CVRx. Shoulder Innovations' average media sentiment score of 0.74 beat CVRx's score of 0.00 indicating that Shoulder Innovations is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CVRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shoulder Innovations 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CVRx (CVRX) Competitors

$4.97 +0.20 (+4.19%)

Closing price 04:00 PM Eastern

Extended Trading

$4.95 -0.02 (-0.40%)

As of 04:30 PM Eastern

Compare

CVRX vs. NPCE, KIDS, CLPT, DCTH, and SI

Should you buy CVRx stock or one of its competitors? MarketBeat compares CVRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CVRx include NeuroPace (NPCE), OrthoPediatrics (KIDS), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), and Shoulder Innovations (SI). These companies are all part of the "medical equipment" industry.

How does CVRx compare to NeuroPace?

CVRx (NASDAQ:CVRX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

NeuroPace has a net margin of -21.67% compared to CVRx's net margin of -89.14%. NeuroPace's return on equity of -108.20% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
NeuroPace	-21.67%	-108.20%	-18.50%

75.3% of CVRx shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CVRx has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

CVRx currently has a consensus target price of $11.50, indicating a potential upside of 131.39%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 21.82%. Given CVRx's higher possible upside, equities research analysts plainly believe CVRx is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

NeuroPace has higher revenue and earnings than CVRx. NeuroPace is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.33	-$53.31M	-$2.02	N/A
NeuroPace	$99.99M	5.27	-$21.47M	-$0.65	N/A

In the previous week, CVRx had 2 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for CVRx and 0 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat CVRx's score of 0.00 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Overall Sentiment
CVRx	Neutral
NeuroPace	Positive

Summary

NeuroPace beats CVRx on 14 of the 17 factors compared between the two stocks.

How does CVRx compare to OrthoPediatrics?

CVRx (NASDAQ:CVRX) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

OrthoPediatrics has higher revenue and earnings than CVRx. OrthoPediatrics is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.33	-$53.31M	-$2.02	N/A
OrthoPediatrics	$243.30M	2.06	-$39.65M	-$1.68	N/A

CVRx has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

In the previous week, OrthoPediatrics had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for OrthoPediatrics and 2 mentions for CVRx. OrthoPediatrics' average media sentiment score of 0.59 beat CVRx's score of 0.00 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OrthoPediatrics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CVRx presently has a consensus price target of $11.50, indicating a potential upside of 131.39%. OrthoPediatrics has a consensus price target of $24.78, indicating a potential upside of 27.13%. Given CVRx's higher possible upside, equities research analysts clearly believe CVRx is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

OrthoPediatrics has a net margin of -16.31% compared to CVRx's net margin of -89.14%. OrthoPediatrics' return on equity of -7.01% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

75.3% of CVRx shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 18.9% of CVRx shares are held by insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

OrthoPediatrics beats CVRx on 12 of the 17 factors compared between the two stocks.

How does CVRx compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

ClearPoint Neuro has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, CVRx has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

ClearPoint Neuro presently has a consensus target price of $23.00, indicating a potential upside of 49.25%. CVRx has a consensus target price of $11.50, indicating a potential upside of 131.39%. Given CVRx's stronger consensus rating and higher probable upside, analysts plainly believe CVRx is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

ClearPoint Neuro has higher earnings, but lower revenue than CVRx. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.50	-$25.54M	-$1.01	N/A
CVRx	$56.65M	2.33	-$53.31M	-$2.02	N/A

In the previous week, CVRx had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 2 mentions for CVRx and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 equaled CVRx'saverage media sentiment score.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
CVRx	Neutral

ClearPoint Neuro has a net margin of -71.57% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
CVRx	-89.14%	-120.76%	-48.38%

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 18.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CVRx beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.

How does CVRx compare to Delcath Systems?

CVRx (NASDAQ:CVRX) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, CVRx had 1 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for CVRx and 1 mentions for Delcath Systems. CVRx's average media sentiment score of 0.00 equaled Delcath Systems'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CVRx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to CVRx's net margin of -89.14%. Delcath Systems' return on equity of 0.51% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Delcath Systems	0.62%	0.51%	0.46%

CVRx presently has a consensus price target of $11.50, indicating a potential upside of 131.39%. Delcath Systems has a consensus price target of $22.17, indicating a potential upside of 73.04%. Given CVRx's stronger consensus rating and higher probable upside, research analysts plainly believe CVRx is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Delcath Systems	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

75.3% of CVRx shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 18.9% of CVRx shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Delcath Systems has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.33	-$53.31M	-$2.02	N/A
Delcath Systems	$85.23M	5.19	$2.70M	$0.01	1,281.00

Summary

Delcath Systems beats CVRx on 10 of the 16 factors compared between the two stocks.

How does CVRx compare to Shoulder Innovations?

CVRx (NASDAQ:CVRX) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Shoulder Innovations had 1 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Shoulder Innovations and 2 mentions for CVRx. Shoulder Innovations' average media sentiment score of 0.74 beat CVRx's score of 0.00 indicating that Shoulder Innovations is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shoulder Innovations	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CVRx presently has a consensus price target of $11.50, indicating a potential upside of 131.39%. Shoulder Innovations has a consensus price target of $21.00, indicating a potential upside of 1.28%. Given CVRx's stronger consensus rating and higher possible upside, research analysts plainly believe CVRx is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Shoulder Innovations has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.33	-$53.31M	-$2.02	N/A
Shoulder Innovations	$47.32M	9.09	-$40.36M	-$166.96	N/A

Shoulder Innovations has a net margin of -81.78% compared to CVRx's net margin of -89.14%. Shoulder Innovations' return on equity of -35.11% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

75.3% of CVRx shares are owned by institutional investors. 18.9% of CVRx shares are owned by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Shoulder Innovations beats CVRx on 10 of the 16 factors compared between the two stocks.

Get CVRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVRX vs. The Competition

Export

Metric	CVRx	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$131.90M	$7.18B	$6.82B	$12.42B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-2.46	49.76	27.00	24.20
Price / Sales	2.33	50.62	519.38	94.43
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	3.31	6.95	10.67	6.26
Net Income	-$53.31M	$162.27M	$3.60B	$331.76M
7 Day Performance	-3.68%	-1.19%	-0.32%	-1.10%
1 Month Performance	0.40%	-2.27%	1.88%	-1.26%
1 Year Performance	-40.05%	5.27%	25.50%	18.84%

CVRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVRX CVRx	1.5712 of 5 stars	$4.97 +4.2%	$11.50 +131.4%	-40.4%	$131.90M	$56.65M	N/A	160	News Coverage
NPCE NeuroPace	2.6808 of 5 stars	$15.95 -6.8%	$18.83 +18.0%	+73.8%	$543.87M	$99.99M	N/A	170
KIDS OrthoPediatrics	2.7408 of 5 stars	$19.25 -7.1%	$24.44 +27.0%	-11.3%	$494.42M	$236.35M	N/A	200
CLPT ClearPoint Neuro	2.7714 of 5 stars	$16.00 -3.1%	$23.00 +43.8%	+36.4%	$479.84M	$36.97M	N/A	110	News Coverage
DCTH Delcath Systems	2.1963 of 5 stars	$13.14 +2.1%	$22.17 +68.7%	+11.9%	$453.49M	$85.23M	1,313.70	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVRX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVRx (CVRX) Competitors

CVRX vs. NPCE, KIDS, CLPT, DCTH, and SI

How does CVRx compare to NeuroPace?

Summary

How does CVRx compare to OrthoPediatrics?

Summary

How does CVRx compare to ClearPoint Neuro?

Summary

How does CVRx compare to Delcath Systems?

Summary

How does CVRx compare to Shoulder Innovations?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRX vs. The Competition

CVRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CVRx (CVRX) Competitors

CVRX vs. NPCE, KIDS, CLPT, DCTH, and SI

How does CVRx compare to NeuroPace?

Is CVRX or NPCE more profitable?

Do institutionals and insiders believe in CVRX or NPCE?

Which has more risk & volatility, CVRX or NPCE?

Do analysts recommend CVRX or NPCE?

Which has preferable valuation & earnings, CVRX or NPCE?

Does the media prefer CVRX or NPCE?

Summary

How does CVRx compare to OrthoPediatrics?

Which has stronger earnings and valuation, CVRX or KIDS?

Which has more volatility & risk, CVRX or KIDS?

Does the media prefer CVRX or KIDS?

Do analysts recommend CVRX or KIDS?

Is CVRX or KIDS more profitable?

Do institutionals & insiders believe in CVRX or KIDS?

Summary

How does CVRx compare to ClearPoint Neuro?

Which has more volatility and risk, CLPT or CVRX?

Do analysts prefer CLPT or CVRX?

Which has preferable valuation and earnings, CLPT or CVRX?

Does the media refer more to CLPT or CVRX?

Is CLPT or CVRX more profitable?

Do institutionals and insiders believe in CLPT or CVRX?

Summary

How does CVRx compare to Delcath Systems?

Does the media prefer CVRX or DCTH?

Which has more risk and volatility, CVRX or DCTH?

Is CVRX or DCTH more profitable?

Do analysts rate CVRX or DCTH?

Do insiders and institutionals believe in CVRX or DCTH?

Which has better earnings and valuation, CVRX or DCTH?

Summary

How does CVRx compare to Shoulder Innovations?

Does the media favor CVRX or SI?

Do analysts prefer CVRX or SI?

Which has better valuation & earnings, CVRX or SI?

Is CVRX or SI more profitable?

Do insiders & institutionals believe in CVRX or SI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRX vs. The Competition

CVRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools